Bosniak III cyst is an indeterminate cystic renal lesion and the first Bosniak category requiring surgical evaluation. According to the 2019 updated Bosniak classification, it may show thick irregular septa or wall (≥4 mm, usually smooth), septa or wall with measurable enhancement (>15-20 HU increase on CT or definite signal increase on MRI), or 1-2 thick enhancing septa. Malignancy risk is approximately 40-60% — about half of lesions are malignant on pathology (usually low-grade cystic RCC). Partial nephrectomy (nephron-sparing surgery) is the first choice. Active surveillance may be an alternative in selected patients (advanced age, comorbidity, small lesion). MRI provides more accurate Bosniak classification than CT due to superior enhancement assessment.
Age Range
40-80
Peak Age
60
Gender
Male predominant
Prevalence
Uncommon
In Bosniak III lesions, measurable enhancement indicates the presence of true vascularization within septa or wall — this may be neoplastic neovascularity (favoring malignancy) or reactive inflammatory vascularization (benign). This is why approximately half are malignant: neovascularity can occur in both tumoral and inflammatory processes. In cystic RCC, tumor cells spread along cyst wall and septa forming a neovascular network — these vessels allow contrast passage producing enhancement. In benign Bosniak III lesions, chronic inflammation, organized hematoma, or infection granulation tissue vascularization causes enhancement. Septal thickening (≥4 mm) reflects tumoral or inflammatory cellular infiltration beyond fibrous band formation — this is the difference between thin septa (fibrous band, avascular) and thick septa (vascularized tissue, cellular infiltration). On CT, measurable enhancement is generally defined as >15-20 HU increase — above the pseudoenhancement threshold reflecting true vascularization. MRI with gadolinium detects small vascular structures more sensitively than CT.
Measurable enhancement increase >15-20 HU in thick septa (≥4 mm) or wall — the key criterion distinguishing Bosniak III from IIF. Confirms true vascularization raising malignancy risk to ~50%. MRI subtraction confirmation recommended.
CT shows thick septa (≥4 mm) and/or thickened cyst wall (≥4 mm) with measurable enhancement. >15-20 HU increase measured on comparison of non-contrast and contrast-enhanced series. Septa are usually smooth and homogeneously thick — nodular thickening or irregular contour favors Bosniak IV. 1-2 thick enhancing septa are sufficient — numerous thick septa may indicate higher malignancy risk.
Report Sentence
Thick septa (≥4 mm) in the renal cystic lesion with measurable enhancement ([x] HU increase); consistent with Bosniak category III, surgical evaluation recommended.
MR contrast-enhanced T1 fat-suppressed sequences show definite enhancement in septa and wall. Subtraction image (post-contrast T1 – pre-contrast T1) definitively demonstrates enhancement — separating from T1 hyperintense structures (hemorrhage, protein). MRI evaluates septal enhancement more sensitively and specifically than CT — improves IIF vs III classification. Thick enhancing septa/wall should be smooth — nodularity suggests Bosniak IV.
Report Sentence
Definitive enhancement confirmed in septa and wall of the cystic lesion on MRI subtraction images; consistent with Bosniak III.
On DWI, Bosniak III lesions show variable signal — simple fluid may appear hyperintense at high b-values due to T2 shine-through, ADC map shows high values (no restriction). Septa/wall may show mild restriction due to thin solid tissue but not mass-like restriction. Focal significant diffusion restriction (low ADC, <1.0 × 10⁻³ mm²/s) favors solid malignant component suggesting Bosniak IV upgrade. DWI is not a primary Bosniak criterion but provides additional information.
Report Sentence
Mild signal on DWI at high b-values due to T2 shine-through without significant restriction on ADC map; no finding favoring solid malignant component.
Cyst wall is thickened ≥4 mm but smooth-contoured. On non-contrast, wall shows homogeneous soft tissue density (40-60 HU) thickening. Measurable enhancement increase on contrast-enhanced series. Smooth thickening favors Bosniak III, irregular/nodular thickening favors Bosniak IV. Wall thickness should be homogeneous — focal thickening or asymmetry raises malignancy suspicion.
Report Sentence
The cystic lesion wall is smoothly thickened ≥4 mm with measurable enhancement on contrast-enhanced series; consistent with Bosniak III.
US shows thick septa (≥4 mm) and/or thickened wall in the cystic lesion. Septa may be hypoechoic or isoechoic. Doppler may demonstrate vascularity within septa — equivalent to CT/MR enhancement. US alone is not sufficient for Bosniak classification — CT or MR confirmation required. CEUS helps evaluate septal enhancement and contributes to Bosniak classification in some centers.
Report Sentence
Thick septa in the renal cystic lesion on US; contrast-enhanced CT or MRI evaluation recommended for Bosniak classification.
Septa and wall may show early enhancement in arterial phase — some cystic RCC have arterial neovascularity. Early enhancement may favor malignancy but is not a primary Bosniak criterion (portal venous phase is primary reference). Multiphasic CT protocol (arterial + portal venous + delayed) allows full enhancement pattern assessment.
Report Sentence
Early enhancement in septa/wall in arterial phase persisting in portal venous phase.
Criteria
1+ thick enhancing septa (≥4 mm), smooth contour, no solid nodule. Most common Bosniak III subtype.
Distinct Features
Malignancy rate ~40-50%. Multilocular cystic nephroma or low-grade cystic RCC common at pathology. Excellent prognosis with partial nephrectomy.
Criteria
Cyst wall thickened ≥4 mm, measurable enhancement, smooth contour. Few or no septa.
Distinct Features
Benign cyst complications (hemorrhage, infection) common — chronic inflammatory wall thickening. Malignancy rate ~50% similar to other subtypes.
Criteria
Both thick enhancing septa and thickened enhancing wall together. More complex morphology.
Distinct Features
Potentially higher malignancy rate. Close to Bosniak IV but remains III due to absence of solid nodule. Surgery more strongly indicated.
Distinguishing Feature
IIF: perceived but not measurable enhancement, septa ≤3 mm. III: measurable enhancement (>15-20 HU), septa ≥4 mm. MRI subtraction provides most accurate distinction.
Distinguishing Feature
Bosniak IV: distinct solid enhancing component (nodule, mass). III: thick enhancing septa/wall but no separate solid component.
Distinguishing Feature
Multilocular cystic nephroma: numerous enhancing septa, no solid component — classified as Bosniak III. Definitive distinction from cystic RCC is pathological.
Distinguishing Feature
Cystic RCC usually Bosniak III or IV. ~50% of Bosniak III lesions are cystic RCC at pathology — imaging cannot definitively distinguish.
Urgency
routineManagement
surgicalBiopsy
Not NeededFollow-up
specialist-referralBosniak III is the first category requiring surgical evaluation — approximately 50% malignancy risk. Partial nephrectomy (nephron-sparing surgery) is the first choice — preserves renal function and has equivalent oncological outcomes for tumors ≤7 cm. Radical nephrectomy is reserved for large (>7 cm), centrally located, or anatomically unsuitable lesions. Active surveillance with 6-monthly MRI may be an alternative in carefully selected patients — advanced age (>75), severe comorbidity, short life expectancy (<5 years), or small lesion (<3 cm). Biopsy is generally not recommended — cystic lesion biopsy is technically challenging (small solid target within fluid), may not be representative, and carries false-negative risk. Even when malignant at surgery, the majority are low-grade cystic RCC (Fuhrman/ISUP grade 1-2) with excellent long-term prognosis — 5-year cancer-specific survival exceeds 95% after complete resection. Multidisciplinary tumor board discussion is recommended for borderline cases. MRI with subtraction technique should be obtained when CT findings are equivocal for definitive Bosniak classification.
Bosniak III cysts carry ~50% malignancy risk. Surgical excision (partial nephrectomy) or active surveillance is recommended. Biopsy may not be reliable. Patient preference and comorbidities should be considered.